The Global Surgical Hemostats Market was valued at USD 3.85 Billion in 2023 and is projected to reach USD 5.62 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period (2023–2030). This growth is being driven by the rising incidence of chronic diseases, increasing number of surgical procedures worldwide, and advancements in hemostatic technologies that promote faster bleeding control and better patient outcomes across various medical settings.

As the healthcare sector evolves with a focus on minimally invasive surgeries and improved recovery times, attention turns to the innovators in hemostasis who deliver reliable solutions for controlling intraoperative bleeding. These tools help to temporarily form blood clots to control bleeding, though their application must remain localized and regulated for safety. In this blog, we profile the Top 10 Companies in the Surgical Hemostats Market—a blend of pharmaceutical giants, medical device specialists, and biotech pioneers advancing the field of surgical hemostasis.

---

🔟 1. Z-Medica

Headquarters: Wallingford, Connecticut, USA
Key Offering: QuikClot hemostatic dressings, chitosan-based agents

Z-Medica specializes in advanced hemostatic products designed primarily for trauma and surgical applications. Their QuikClot line, featuring kaolin-impregnated gauze, is widely used in emergency and surgical environments to accelerate clotting without the need for pressure or tourniquets in many cases. The company has built a strong reputation through collaborations with military and civilian healthcare providers, ensuring their products meet rigorous standards for rapid efficacy and biocompatibility.

Innovation Initiatives:

• Development of non-absorbable hemostats for external wounds transitioning to surgical use
• Partnerships with defense agencies for enhanced trauma care technologies
• Ongoing R&D in zeolite-free formulations to minimize heat generation during clotting

Download FREE Sample Report: Surgical Hemostats Market – View in Detailed Research Report

---

9️⃣ 2. C. R. Bard (BD)

Headquarters: Franklin Lakes, New Jersey, USA
Key Offering: ARISTOTLE thrombin topical solution, collagen-based hemostats

Now part of Becton Dickinson, C. R. Bard has long been a key player in vascular and surgical hemostasis. Their portfolio includes thrombin solutions that promote rapid fibrin formation, essential for procedures involving high bleeding risk. Bard’s products are integral in cardiovascular and general surgeries, where precise bleeding management can significantly impact recovery. The integration with BD has expanded their global distribution and R&D capabilities, allowing for broader adoption in hospital settings.

Innovation Initiatives:

• Integration of bovine thrombin alternatives to reduce immunogenicity risks
• Expansion of topical hemostats for endoscopic procedures
• Collaborative studies on long-term safety in minimally invasive applications

---

8️⃣ 3. CryoLife

Headquarters: Kennesaw, Georgia, USA
Key Offering: BioGlue surgical adhesive, thrombin hemostats

CryoLife focuses on bio-surgical solutions, including hemostatic sealants that combine synthetic and biological materials for robust bleeding control. BioGlue, their flagship product, is particularly valued in cardiac and vascular surgeries for sealing tissues and preventing leaks. The company’s emphasis on cryopreserved tissues and adhesives has positioned it as a leader in complex procedures, where traditional methods fall short. Their innovations continue to evolve with surgeon feedback, enhancing ease of use and efficacy.

Innovation Initiatives:

• Advancements in synthetic sealants compatible with robotic surgery
• Clinical trials for expanded indications in neurosurgery
• Focus on reducing inflammatory responses in hemostatic applications

---

7️⃣ 4. Marine Polymer Technologies

Headquarters: Wakefield, Massachusetts, USA
Key Offering: Hemaseel hemostatic patch, chitosan-derived products

Marine Polymer Technologies leverages marine-derived chitosan for its unique hemostatic properties, offering products that work independently of the coagulation cascade. Their Hemaseel patch is designed for topical application in surgeries requiring immediate adhesion and clotting. This biotech firm stands out for its eco-friendly sourcing and biocompatible materials, appealing to surgeons seeking alternatives to animal-derived agents. Their research pipeline emphasizes scalability for broader surgical adoption.

Innovation Initiatives:

• Exploration of plant-based chitosan for cost-effective production
• Partnerships for integrating hemostats into laparoscopic tools
• Studies on antimicrobial properties to prevent post-surgical infections

Download FREE Sample Report: Surgical Hemostats Market – View in Detailed Research Report

---

6️⃣ 5. CSL Behring

Headquarters: King of Prussia, Pennsylvania, USA
Key Offering: Beriplast P thrombin sealant, fibrinogen-based hemostats

CSL Behring, a global biotechnology leader, provides plasma-derived hemostatic agents that mimic the body’s natural clotting process. Beriplast is a two-component sealant used in various surgeries, from general to orthopedic, offering strong adhesion and minimal residue. The company’s deep expertise in immunology and hematology ensures high-purity products, reducing complication risks. They serve major hospitals and surgical centers, contributing significantly to market growth through reliable supply chains.

Innovation Initiatives:

• Development of recombinant thrombin to avoid viral transmission concerns
• Expansion into pediatric surgical applications
• International collaborations for regulatory approvals in emerging markets

---

5️⃣ 6. Grifols

Headquarters: Barcelona, Spain
Key Offering: Tisseel fibrin sealant, plasma-derived hemostats

Grifols excels in hemoderivatives, with Tisseel being a versatile fibrin glue for tissue sealing and hemostasis in challenging surgical environments. This product is applied in thoracic, neurosurgical, and trauma cases, where it provides both adhesive and hemostatic functions. The company’s European roots have facilitated strong presence in regulated markets, while their investment in plasma collection ensures steady production. Grifols continues to innovate by refining application devices for precision.

Innovation Initiatives:

• Enhancements in sprayable formulations for large surface areas
• R&D on virus-inactivated processes for safer products
• Trials for use in transplant surgeries to promote graft adhesion

---

4️⃣ 7. Integra LifeSciences

Headquarters: Plainsboro, New Jersey, USA
Key Offering: Surgiflo hemostatic matrix, gelatin-based agents

Integra LifeSciences offers absorbable hemostats like Surgiflo, which expands upon contact with blood to form clots in general and specialty surgeries. Their focus on regenerative technologies complements hemostasis, aiding wound healing post-procedure. Widely used in hospitals and ambulatory centers, these products reduce operation times and blood loss. Integra’s commitment to neurosurgery and orthopedics has driven product diversification and market penetration.

Innovation Initiatives:

• Integration of thrombin within matrices for faster action
• Development for minimally invasive delivery systems
• Research into bioresorbable materials for reduced foreign body reactions

Download FREE Sample Report: Surgical Hemostats Market – View in Detailed Research Report

---

3️⃣ 8. Teleflex

Headquarters: Wayne, Pennsylvania, USA
Key Offering: QuikFIX vascular hemostasis, collagen plugs

Teleflex provides hemostatic devices for vascular access and closure, crucial in interventional procedures. Their collagen-based plugs facilitate quick sealing after catheterization, minimizing complications in cardiology and radiology suites. The company’s portfolio supports both open and minimally invasive techniques, aligning with trends toward outpatient care. Teleflex’s global operations ensure accessibility, with ongoing improvements in deployment mechanisms for user-friendliness.

Innovation Initiatives:

• Advancements in suture-mediated closure devices
• Focus on antimicrobial coatings to prevent access-site infections
• Expansion into peripheral vascular applications

---

2️⃣ 9. B. Braun

Headquarters: Melsungen, Germany
Key Offering: TachoSil fibrin patch, combination hemostats

B. Braun delivers comprehensive surgical solutions, including the TachoSil patch that combines collagen and fibrinogen for effective hemostasis in hepatic, thoracic, and urologic surgeries. This ready-to-use product simplifies application and is absorbable, reducing the need for removal. As a family-owned enterprise, B. Braun emphasizes quality and innovation, serving diverse healthcare facilities worldwide and contributing to reduced surgical times through reliable performance.

Innovation Initiatives:

• Customization of patches for robotic and laparoscopic use
• Studies on equine collagen for hypoallergenic alternatives
• Partnerships for integrating hemostats with surgical robotics

---

1️⃣ 10. Johnson & Johnson (Ethicon)

Headquarters: New Brunswick, New Jersey, USA
Key Offering: Surgicel oxidized cellulose, Evicel fibrin sealant

Through its Ethicon division, Johnson & Johnson dominates the surgical hemostats landscape with a broad range of absorbable agents like Surgicel, used extensively in gynecological, general, and trauma surgeries for broad-area bleeding control. Evicel offers a human plasma-derived sealant for precision applications. J&J’s extensive R&D and global reach make it a market leader, influencing standards in hemostasis and supporting millions of procedures annually with safe, effective solutions.

Innovation Initiatives:

• Next-generation bioengineered sealants for chronic wound management
• Massive investments in AI-assisted surgical planning with hemostat integration
• Global trials for expanded use in outpatient and emergency settings

Get Full Report Here: Surgical Hemostats Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Surgical Hemostats Is Innovative and Precise

The surgical hemostats market is experiencing steady evolution. While traditional absorbable agents remain staples, investments in advanced materials, delivery systems, and combination therapies are reshaping the landscape to meet demands for faster, safer procedures.

📈 Key Trends Shaping the Market:

• Increasing adoption of minimally invasive hemostats in Asia-Pacific and Europe
• Regulatory advancements supporting bio-based and recombinant products by 2030
• Digital integration for real-time bleeding monitoring during surgeries
• Strategic alliances between device makers and hospitals for customized solutions

Get Full Report Here: Surgical Hemostats Market – View in Detailed Research Report

The companies listed above are not only controlling bleeding in surgeries—they’re leading the shift toward advanced, patient-centered care in operating rooms worldwide.